[{"orgOrder":0,"company":"Navega Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"NT-Z001","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Navega Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Navega Therapeutics \/ Navega Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Navega Therapeutics \/ Navega Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Navega Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration supports Navega's NT-Z001 for chronic pain in rare diseases like small fiber neuropathy and primary erythromelalgia.

                          Brand Name : NT-Z001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 14, 2024

                          Lead Product(s) : NT-Z001

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Recipient : Charles River Laboratories, Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank